You are eating the same way you always have, moving the same way, and the scale will not budge, or it climbs. If that shift lined up with broken sleep, mood swings, and an unpredictable cycle, you are not imagining a connection. Estrogen and insulin talk to each other, and understanding that conversation changes how a thoughtful provider approaches a plateau.

Why the wall feels new (and why it is not a willpower problem)

Perimenopause is the transition into menopause, and it can start years before periods stop. During this window, estrogen does not simply decline in a straight line: it fluctuates, sometimes wildly, before its eventual fall [1]. Those swings help explain the foreign-feeling mood shifts, the fractured sleep, and the sense that your body changed the rules overnight.

One of estrogen's quieter jobs is helping your body respond to insulin, the hormone that moves sugar out of your blood and into cells for energy. Estrogen, acting largely through the estrogen receptor alpha, supports insulin sensitivity and healthy glucose handling [2][3]. As estrogen becomes erratic and then lower, many women notice their metabolism responding differently: fat that once sat on the hips and thighs tends to migrate toward the abdomen, and that visceral (deep-belly) fat is more metabolically active and more strongly linked to insulin resistance [3][4].

So the perimenopausal weight-loss wall is often not one problem. It is a hormonal shift and a metabolic shift happening at the same time, feeding each other. Treating them as separate issues, or reducing it to "eat less," misses how tightly they are linked.

Insulin resistance, in plain English

Insulin resistance means your cells have grown less responsive to insulin's signal, so your pancreas pumps out more of it to get the same job done. Higher circulating insulin makes it harder to release stored fat and easier to store more, and it can drive the cravings and afternoon crashes that make a ten-hour day feel impossible.

This is not unique to perimenopause. Younger women with irregular cycles, acne, and stubborn central weight are often navigating a related picture, sometimes described as PCOS or PCOS-adjacent, where insulin resistance is a central feature [5]. In both cases, the middle-of-the-body weight and the cycle changes may be downstream of the same metabolic story, which is exactly why bloodwork matters more than a bathroom scale.

A1c reference points a provider may reference
< 5.7%Normal A1cBelow the prediabetes range
5.7-6.4%PrediabetesDefined by the ADA
≥ 6.5%DiabetesOn the ADA A1c criterion

Source: [6] Diagnosis - Standards of Care, American Diabetes Association

What an independent provider actually reviews before considering a GLP-1

GLP-1 based medications (the class that includes molecules like semaglutide and tirzepatide) act on metabolic pathways, but they are not a substitute for understanding your baseline. Through the Velri clinical review process, an independent provider looks at hormones and metabolic markers together, not as separate errands. Depending on your history, that review commonly includes:

  • Glucose and A1c. Fasting glucose and hemoglobin A1c (a roughly three-month average of blood sugar) help place you on the spectrum from normal to prediabetes to diabetes. The American Diabetes Association defines prediabetes as an A1c of 5.7 to 6.4 percent [6].
  • Insulin and related markers. Fasting insulin, sometimes paired with glucose, gives a window into insulin resistance that A1c alone can miss.
  • A lipid panel. Cholesterol and triglycerides often shift alongside insulin resistance and the menopause transition [3].
  • Thyroid function. Thyroid problems can mimic or worsen fatigue, weight change, and mood symptoms, so they are worth ruling in or out.
  • Hormonal context. Cycle history, symptom patterns, and, when appropriate, hormone-related labs help distinguish a perimenopausal picture from a PCOS-adjacent one, because the same weight complaint can have different drivers.

The point of reviewing these together is simple: your estrogen story and your insulin story are not in separate charts in your body, so they should not be reviewed in separate silos. A provider who sees the whole picture can talk through whether a metabolic medication fits, whether hormone-related support is worth discussing, whether lifestyle levers should come first, or some combination. A prescription is never guaranteed. It is a clinical decision made by an independent licensed provider based on your labs, history, and goals.

Where A1c falls: normal, prediabetes, diabetes
Normal ≤5.7Prediabetes ≤6.5Diabetes ≤7

% A1c · marker = Prediabetes threshold

Source: [6] Diagnosis - Standards of Care, American Diabetes Association

How the review sequence tends to flow
1LabsGlucose, A1c, insulin, lipids, thyroid
2Provider reviewHormones and metabolic markers together
3Shared planLifestyle, and medication only if appropriate
4Follow-upReassess based on your data

Source: [6] Diagnosis - Standards of Care, American Diabetes Association, [7] Glucagon-Like Peptide-1 Receptor Agonists (PubMed, StatPearls / NCBI Bookshelf)

Where GLP-1 medications fit into the conversation

GLP-1 (glucagon-like peptide-1) is a hormone your gut naturally releases after eating. It nudges insulin release when blood sugar is high and influences appetite signaling [7]. Medications in this class engage those same pathways, which is why they come up in metabolic conversations. Whether any medication, oral or injectable, is appropriate is a decision for a licensed provider after review, and it is only one possible part of a plan.

If a provider prescribes a compounded medication, one important note applies. Compounded medications are not reviewed or approved by the FDA for safety, effectiveness, or quality. Compounded products are not equivalent to or interchangeable with any FDA-approved brand-name drug. Availability varies by state.

This article is educational and is not medical advice. It is not a recommendation to take any specific drug, and it does not replace a conversation with a qualified clinician who knows your history.

If you have been dismissed before

Being told you are "too young" for perimenopause, or to "just lose weight" without a single lab drawn, is a real and common frustration. Perimenopause can begin in the early forties or sooner, and metabolic changes deserve to be measured rather than assumed. The useful next step is rarely a lecture. It is data: labs that explain what your body is actually doing, reviewed by someone who takes the whole pattern seriously.

Where Velri fits

Velri is a technology and coordination company, not a medical practice. Velri does not provide medical care. What Velri coordinates is the practical scaffolding around that care: helping arrange lab work, connecting you with an independent, physician-led Provider Group for a visit where hormones and metabolic markers can be reviewed together, and, if an independent provider decides a medication is appropriate, coordinating fulfillment through an independent, licensed pharmacy.

Velri's coordinated services are starting in Nevada, with more states rolling out over time. Nothing here promises a diagnosis, a prescription, or a particular result. It offers a path to being taken seriously, measured properly, and reviewed as a whole person rather than a single number on a scale.